Share Price and Basic Stock Data
Last Updated: February 9, 2026, 8:18 pm
| PEG Ratio | 0.50 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ajooni Biotech Ltd operates in the animal and shrimp feed industry, with a current market capitalization of ₹73.6 Cr. The company reported a price of ₹4.27 per share and has shown a notable revenue trajectory. In the fiscal year ending March 2023, sales stood at ₹74 Cr, maintaining the same level as the previous year. However, revenue trends indicate fluctuations in quarterly performance, with sales reaching a peak of ₹41.26 Cr in March 2023 before declining to ₹19.48 Cr in September 2023. The company’s trailing twelve-month (TTM) revenue is reported at ₹126 Cr, suggesting a recovery phase after experiencing seasonal variations. Ajooni’s operational performance reflects the challenges of the shrimp feed market, which is sensitive to supply chain disruptions and changes in demand. The overall growth strategy appears to hinge on enhancing production efficiency and market expansion. The company’s ability to stabilize revenue in the upcoming quarters will be crucial for maintaining investor confidence and market position.
Profitability and Efficiency Metrics
Profitability metrics for Ajooni Biotech Ltd reveal a mixed performance, with a reported operating profit margin (OPM) of 4.73%. Over recent quarters, the OPM fluctuated, with a notable decline to -3.24% in December 2023, indicating potential operational inefficiencies. The net profit for the same period was ₹4 Cr, reflecting a slight increase from ₹1 Cr in the previous fiscal year. The return on equity (ROE) stood at 5.15%, while the return on capital employed (ROCE) was reported at 6.91%. The company’s interest coverage ratio (ICR) of 17.22x suggests a strong ability to meet interest obligations, which is a positive indicator of financial health. The cash conversion cycle (CCC) of 129 days indicates inefficiencies in managing working capital, particularly in inventory and receivables. These profitability and efficiency metrics highlight areas for improvement, particularly in cost management and operational streamlining, to enhance overall financial performance.
Balance Sheet Strength and Financial Ratios
Ajooni Biotech Ltd’s balance sheet reflects a conservative approach to leverage, with total borrowings amounting to ₹9 Cr against reserves of ₹55 Cr. The company’s debt-to-equity ratio stands at a low 0.06, indicating minimal reliance on external financing. The book value per share is reported at ₹5.11, and the price-to-book value (P/BV) ratio is 1.10x, suggesting that the stock is trading at a slight premium to its book value. The current ratio of 12.86x indicates a robust liquidity position, significantly higher than typical sector ranges, which often hover closer to 1.5-2.0x. However, the inventory turnover ratio of 5.83x and accounts receivable days of 101 reflect potential inefficiencies in inventory management and collections. Overall, while Ajooni Biotech displays strong liquidity and low leverage, it faces challenges in operational efficiency that could impact long-term sustainability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ajooni Biotech Ltd reveals a diverse ownership structure, with promoters holding 26.89% of the equity. The public holds a significant 73.11%, indicating broad retail participation, while foreign institutional investors (FIIs) have negligible presence at 0.00%. The number of shareholders has increased from 16,429 in December 2022 to 64,305 in September 2025, demonstrating growing interest and confidence among retail investors. However, the declining promoter stake from 36.39% in March 2023 to the current level raises questions about insider confidence in the company’s future prospects. This shift may affect market perceptions and investor sentiment. With a lack of institutional backing, the company may need to focus on enhancing operational performance and profitability to maintain investor interest and support share price stability.
Outlook, Risks, and Final Insight
The outlook for Ajooni Biotech Ltd hinges on its ability to address operational inefficiencies while capitalizing on the growing demand for shrimp feed. Key strengths include a solid liquidity position, low debt levels, and a broad shareholder base, which can provide stability during challenging market conditions. However, risks include the potential volatility in sales and profit margins, as evidenced by recent fluctuations in quarterly performance. Additionally, the company’s reliance on the domestic shrimp feed market, which is subject to regulatory changes and environmental factors, poses inherent risks. If Ajooni can enhance its operational efficiency and manage its cash conversion cycle effectively, it may strengthen its market position. Conversely, failure to address these challenges could hinder growth and investor confidence, leading to potential declines in share performance in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Narmada Agrobase Ltd | 124 Cr. | 32.6 | 33.6/14.6 | 32.4 | 15.3 | 0.00 % | 13.0 % | 11.2 % | 10.0 |
| Godrej Agrovet Ltd | 11,194 Cr. | 582 | 876/506 | 24.3 | 94.1 | 1.89 % | 16.6 % | 17.7 % | 10.0 |
| Avanti Feeds Ltd | 15,022 Cr. | 1,104 | 1,141/582 | 24.3 | 221 | 0.82 % | 24.0 % | 19.5 % | 1.00 |
| Ajooni Biotech Ltd | 87.3 Cr. | 5.07 | 7.74/3.55 | 17.8 | 5.29 | 0.00 % | 6.91 % | 5.15 % | 2.00 |
| Industry Average | 8,780.00 Cr | 430.92 | 24.70 | 83.92 | 0.68% | 15.13% | 13.39% | 5.75 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.63 | 41.26 | 21.00 | 19.48 | 20.05 | 19.58 | 25.66 | 25.72 | 34.03 | 29.27 | 31.27 | 31.74 | 58.75 |
| Expenses | 10.15 | 40.32 | 20.34 | 18.85 | 20.70 | 17.99 | 24.70 | 24.95 | 33.10 | 28.26 | 30.56 | 30.24 | 55.72 |
| Operating Profit | 0.48 | 0.94 | 0.66 | 0.63 | -0.65 | 1.59 | 0.96 | 0.77 | 0.93 | 1.01 | 0.71 | 1.50 | 3.03 |
| OPM % | 4.52% | 2.28% | 3.14% | 3.23% | -3.24% | 8.12% | 3.74% | 2.99% | 2.73% | 3.45% | 2.27% | 4.73% | 5.16% |
| Other Income | 0.02 | 0.26 | 0.07 | 0.29 | 1.57 | 0.26 | 0.04 | 0.31 | 0.39 | 1.34 | 0.65 | 0.15 | 0.32 |
| Interest | 0.13 | 0.12 | 0.13 | 0.19 | 0.12 | 0.11 | 0.15 | 0.06 | 0.07 | 0.06 | 0.08 | 0.17 | 0.18 |
| Depreciation | 0.26 | 0.24 | 0.21 | 0.21 | 0.21 | 0.24 | 0.22 | 0.23 | 0.24 | 0.38 | 0.25 | 0.25 | 0.81 |
| Profit before tax | 0.11 | 0.84 | 0.39 | 0.52 | 0.59 | 1.50 | 0.63 | 0.79 | 1.01 | 1.91 | 1.03 | 1.23 | 2.36 |
| Tax % | 0.00% | 35.71% | -2.56% | 23.08% | 23.73% | 38.67% | 25.40% | 22.78% | 27.72% | 19.37% | 24.27% | 24.39% | 30.08% |
| Net Profit | 0.11 | 0.54 | 0.40 | 0.40 | 0.44 | 0.91 | 0.47 | 0.62 | 0.73 | 1.54 | 0.78 | 0.93 | 1.65 |
| EPS in Rs | 0.01 | 0.03 | 0.02 | 0.02 | 0.03 | 0.05 | 0.03 | 0.04 | 0.04 | 0.09 | 0.05 | 0.05 | 0.10 |
Last Updated: February 6, 2026, 10:47 pm
Below is a detailed analysis of the quarterly data for Ajooni Biotech Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 58.75 Cr.. The value appears strong and on an upward trend. It has increased from 31.74 Cr. (Sep 2025) to 58.75 Cr., marking an increase of 27.01 Cr..
- For Expenses, as of Dec 2025, the value is 55.72 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 30.24 Cr. (Sep 2025) to 55.72 Cr., marking an increase of 25.48 Cr..
- For Operating Profit, as of Dec 2025, the value is 3.03 Cr.. The value appears strong and on an upward trend. It has increased from 1.50 Cr. (Sep 2025) to 3.03 Cr., marking an increase of 1.53 Cr..
- For OPM %, as of Dec 2025, the value is 5.16%. The value appears strong and on an upward trend. It has increased from 4.73% (Sep 2025) to 5.16%, marking an increase of 0.43%.
- For Other Income, as of Dec 2025, the value is 0.32 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2025) to 0.32 Cr., marking an increase of 0.17 Cr..
- For Interest, as of Dec 2025, the value is 0.18 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.17 Cr. (Sep 2025) to 0.18 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Dec 2025, the value is 0.81 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.25 Cr. (Sep 2025) to 0.81 Cr., marking an increase of 0.56 Cr..
- For Profit before tax, as of Dec 2025, the value is 2.36 Cr.. The value appears strong and on an upward trend. It has increased from 1.23 Cr. (Sep 2025) to 2.36 Cr., marking an increase of 1.13 Cr..
- For Tax %, as of Dec 2025, the value is 30.08%. The value appears to be increasing, which may not be favorable. It has increased from 24.39% (Sep 2025) to 30.08%, marking an increase of 5.69%.
- For Net Profit, as of Dec 2025, the value is 1.65 Cr.. The value appears strong and on an upward trend. It has increased from 0.93 Cr. (Sep 2025) to 1.65 Cr., marking an increase of 0.72 Cr..
- For EPS in Rs, as of Dec 2025, the value is 0.10. The value appears strong and on an upward trend. It has increased from 0.05 (Sep 2025) to 0.10, marking an increase of 0.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:44 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 7 | 13 | 29 | 42 | 40 | 40 | 51 | 74 | 74 | 80 | 115 | 126 |
| Expenses | 1 | 7 | 13 | 28 | 41 | 39 | 39 | 49 | 71 | 72 | 78 | 111 | 122 |
| Operating Profit | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 4 | 4 |
| OPM % | 2% | 2% | 2% | 2% | 2% | 2% | 3% | 3% | 4% | 4% | 3% | 3% | 3% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 5 |
| Tax % | 0% | 27% | 29% | 28% | 20% | 15% | 29% | 26% | 28% | 28% | 28% | 22% | |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 4 |
| EPS in Rs | 0.02 | 0.12 | 0.18 | 0.36 | 0.03 | 0.03 | 0.02 | 0.02 | 0.05 | 0.06 | 0.12 | 0.20 | 0.23 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 100.00% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 100.00% | -50.00% |
Ajooni Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 23% |
| 3 Years: | 16% |
| TTM: | 42% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 47% |
| 5 Years: | 56% |
| 3 Years: | 47% |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -19% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 4, 2025, 9:40 pm
Balance Sheet
Last Updated: January 7, 2026, 3:17 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.24 | 0.24 | 0.24 | 0.33 | 6 | 6 | 8 | 10 | 10 | 18 | 18 | 34 | 34 |
| Reserves | 0 | 0 | 0 | 1 | 5 | 6 | 7 | 6 | 6 | 24 | 25 | 54 | 55 |
| Borrowings | 0 | 0 | 1 | 1 | 5 | 5 | 5 | 7 | 5 | 5 | 2 | 2 | 9 |
| Other Liabilities | 0 | 1 | 1 | 11 | 4 | 1 | 2 | 6 | 7 | 12 | 3 | 5 | 5 |
| Total Liabilities | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 | 104 |
| Fixed Assets | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 5 | 6 | 6 | 10 | 11 | 11 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 11 |
| Investments | 0 | 0 | 0 | 6 | 6 | 4 | 3 | 1 | 1 | 4 | 2 | 3 | 3 |
| Other Assets | 0 | 1 | 2 | 6 | 12 | 13 | 18 | 22 | 22 | 48 | 34 | 80 | 78 |
| Total Assets | 0 | 2 | 2 | 13 | 19 | 18 | 23 | 28 | 29 | 59 | 48 | 95 | 104 |
Below is a detailed analysis of the balance sheet data for Ajooni Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 34.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 34.00 Cr..
- For Reserves, as of Sep 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 1.00 Cr..
- For Borrowings, as of Sep 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 95.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 9.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 78.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2025) to 78.00 Cr., marking a decrease of 2.00 Cr..
- For Total Assets, as of Sep 2025, the value is 104.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Mar 2025) to 104.00 Cr., marking an increase of 9.00 Cr..
Notably, the Reserves (55.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | 0.00 | -1.00 | 0.00 | -4.00 | -4.00 | -4.00 | -5.00 | -2.00 | -2.00 | 0.00 | 2.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 40 | 33 | 17 | 25 | 44 | 115 | 98 | 68 | 101 | 59 | 52 |
| Inventory Days | 141 | 22 | 14 | 63 | 19 | 51 | 34 | 46 | 34 | 39 | 80 | 90 |
| Days Payable | 100 | 66 | 27 | 79 | 9 | 12 | 20 | 46 | 39 | 56 | 8 | 13 |
| Cash Conversion Cycle | 99 | -4 | 20 | 1 | 35 | 84 | 129 | 98 | 63 | 83 | 131 | 129 |
| Working Capital Days | 96 | 5 | 9 | -29 | -1 | 84 | 105 | 77 | 58 | 94 | 132 | 160 |
| ROCE % | 28% | 18% | 37% | 10% | 4% | 4% | 5% | 9% | 6% | 8% | 7% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Diluted EPS (Rs.) | 0.20 | 0.25 | 1.94 | 1.05 | 0.37 |
| Cash EPS (Rs.) | 0.25 | 0.34 | 0.24 | 2.16 | 0.95 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 5.11 | 4.87 | 4.76 | 16.37 | 15.64 |
| Revenue From Operations / Share (Rs.) | 6.66 | 9.14 | 8.50 | 74.00 | 51.01 |
| PBDIT / Share (Rs.) | 0.33 | 0.50 | 0.34 | 3.11 | 1.66 |
| PBIT / Share (Rs.) | 0.27 | 0.40 | 0.23 | 2.00 | 1.09 |
| PBT / Share (Rs.) | 0.25 | 0.34 | 0.17 | 1.46 | 0.50 |
| Net Profit / Share (Rs.) | 0.19 | 0.24 | 0.12 | 1.05 | 0.37 |
| PBDIT Margin (%) | 5.01 | 5.52 | 4.10 | 4.20 | 3.26 |
| PBIT Margin (%) | 4.06 | 4.43 | 2.75 | 2.70 | 2.13 |
| PBT Margin (%) | 3.77 | 3.73 | 2.11 | 1.97 | 0.98 |
| Net Profit Margin (%) | 2.94 | 2.69 | 1.50 | 1.41 | 0.73 |
| Return on Networth / Equity (%) | 3.82 | 5.06 | 2.69 | 6.40 | 2.38 |
| Return on Capital Employeed (%) | 5.16 | 7.98 | 4.72 | 10.55 | 6.20 |
| Return On Assets (%) | 3.54 | 4.54 | 1.91 | 3.61 | 1.33 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.04 | 0.15 | 0.12 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.12 | 0.32 | 0.43 |
| Asset Turnover Ratio (%) | 1.61 | 1.51 | 1.70 | 2.60 | 2.00 |
| Current Ratio (X) | 12.86 | 10.74 | 2.28 | 2.18 | 2.05 |
| Quick Ratio (X) | 7.89 | 5.63 | 1.82 | 1.60 | 1.53 |
| Inventory Turnover Ratio (X) | 5.83 | 6.25 | 10.27 | 11.35 | 10.01 |
| Interest Coverage Ratio (X) | 17.22 | 7.95 | 6.40 | 5.76 | 2.85 |
| Interest Coverage Ratio (Post Tax) (X) | 11.09 | 4.88 | 3.35 | 2.94 | 1.64 |
| Enterprise Value (Cr.) | 95.06 | 53.43 | 39.48 | 72.63 | 36.96 |
| EV / Net Operating Revenue (X) | 0.82 | 0.66 | 0.52 | 0.98 | 0.72 |
| EV / EBITDA (X) | 16.51 | 12.07 | 12.90 | 23.34 | 22.19 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| Price / BV (X) | 1.10 | 1.21 | 0.83 | 4.11 | 1.94 |
| Price / Net Operating Revenue (X) | 0.84 | 0.64 | 0.46 | 0.90 | 0.59 |
| EarningsYield | 0.03 | 0.04 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Ajooni Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 5. It has decreased from 0.25 (Mar 24) to 0.20, marking a decrease of 0.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 5.11. It has increased from 4.87 (Mar 24) to 5.11, marking an increase of 0.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.66. It has decreased from 9.14 (Mar 24) to 6.66, marking a decrease of 2.48.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 2. It has decreased from 0.50 (Mar 24) to 0.33, marking a decrease of 0.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.27. This value is within the healthy range. It has decreased from 0.40 (Mar 24) to 0.27, marking a decrease of 0.13.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.25. This value is within the healthy range. It has decreased from 0.34 (Mar 24) to 0.25, marking a decrease of 0.09.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 2. It has decreased from 0.24 (Mar 24) to 0.19, marking a decrease of 0.05.
- For PBDIT Margin (%), as of Mar 25, the value is 5.01. This value is below the healthy minimum of 10. It has decreased from 5.52 (Mar 24) to 5.01, marking a decrease of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 4.06. This value is below the healthy minimum of 10. It has decreased from 4.43 (Mar 24) to 4.06, marking a decrease of 0.37.
- For PBT Margin (%), as of Mar 25, the value is 3.77. This value is below the healthy minimum of 10. It has increased from 3.73 (Mar 24) to 3.77, marking an increase of 0.04.
- For Net Profit Margin (%), as of Mar 25, the value is 2.94. This value is below the healthy minimum of 5. It has increased from 2.69 (Mar 24) to 2.94, marking an increase of 0.25.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.82. This value is below the healthy minimum of 15. It has decreased from 5.06 (Mar 24) to 3.82, marking a decrease of 1.24.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.16. This value is below the healthy minimum of 10. It has decreased from 7.98 (Mar 24) to 5.16, marking a decrease of 2.82.
- For Return On Assets (%), as of Mar 25, the value is 3.54. This value is below the healthy minimum of 5. It has decreased from 4.54 (Mar 24) to 3.54, marking a decrease of 1.00.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.61. It has increased from 1.51 (Mar 24) to 1.61, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 12.86. This value exceeds the healthy maximum of 3. It has increased from 10.74 (Mar 24) to 12.86, marking an increase of 2.12.
- For Quick Ratio (X), as of Mar 25, the value is 7.89. This value exceeds the healthy maximum of 2. It has increased from 5.63 (Mar 24) to 7.89, marking an increase of 2.26.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has decreased from 6.25 (Mar 24) to 5.83, marking a decrease of 0.42.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 17.22. This value is within the healthy range. It has increased from 7.95 (Mar 24) to 17.22, marking an increase of 9.27.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 11.09, marking an increase of 6.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 95.06. It has increased from 53.43 (Mar 24) to 95.06, marking an increase of 41.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.82, marking an increase of 0.16.
- For EV / EBITDA (X), as of Mar 25, the value is 16.51. This value exceeds the healthy maximum of 15. It has increased from 12.07 (Mar 24) to 16.51, marking an increase of 4.44.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For Price / BV (X), as of Mar 25, the value is 1.10. This value is within the healthy range. It has decreased from 1.21 (Mar 24) to 1.10, marking a decrease of 0.11.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has increased from 0.64 (Mar 24) to 0.84, marking an increase of 0.20.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajooni Biotech Ltd:
- Net Profit Margin: 2.94%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.16% (Industry Average ROCE: 15.13%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.82% (Industry Average ROE: 13.39%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 11.09
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 7.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.8 (Industry average Stock P/E: 24.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.94%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Animal/Shrimp Feed | D-118, Industrial Area, Phase - VII, Mohali Punjab 160055 | info@ajoonibiotech.com http://www.ajoonibiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jasjot Singh | Managing Director & CFO |
| Mr. Gursimran Singh | Whole Time Director |
| Mr. Partek Singh | Director |
| Mr. Ramandeep Singh | Independent Director |
| Mr. Imteshwar Singh | Independent Director |
| Ms. Simmi Chabbra | Independent Director |
| Mr. Ishtneet Bhatia | Independent Director |
FAQ
What is the intrinsic value of Ajooni Biotech Ltd?
Ajooni Biotech Ltd's intrinsic value (as of 09 February 2026) is ₹5.37 which is 5.92% higher the current market price of ₹5.07, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹87.3 Cr. market cap, FY2025-2026 high/low of ₹7.74/3.55, reserves of ₹55 Cr, and liabilities of ₹104 Cr.
What is the Market Cap of Ajooni Biotech Ltd?
The Market Cap of Ajooni Biotech Ltd is 87.3 Cr..
What is the current Stock Price of Ajooni Biotech Ltd as on 09 February 2026?
The current stock price of Ajooni Biotech Ltd as on 09 February 2026 is ₹5.07.
What is the High / Low of Ajooni Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajooni Biotech Ltd stocks is ₹7.74/3.55.
What is the Stock P/E of Ajooni Biotech Ltd?
The Stock P/E of Ajooni Biotech Ltd is 17.8.
What is the Book Value of Ajooni Biotech Ltd?
The Book Value of Ajooni Biotech Ltd is 5.29.
What is the Dividend Yield of Ajooni Biotech Ltd?
The Dividend Yield of Ajooni Biotech Ltd is 0.00 %.
What is the ROCE of Ajooni Biotech Ltd?
The ROCE of Ajooni Biotech Ltd is 6.91 %.
What is the ROE of Ajooni Biotech Ltd?
The ROE of Ajooni Biotech Ltd is 5.15 %.
What is the Face Value of Ajooni Biotech Ltd?
The Face Value of Ajooni Biotech Ltd is 2.00.